Wilson Therapeutics AB Stock

Wilson Therapeutics AB is a Sweden-based biopharmaceutical company that is active in the development of a treatment for Wilson disease. Wilson disease is a genetic disease that causes copper poisoning. The Company's main product is Decuprate (tetrathiomolybdate), a de-coppering agent with a mechanism of action enabling it to bind copper to restore, in part or in whole, the body's own buffer system for copper in the liver. Decuprate also restores the natural excretion route via the bile rather than preventing copper to be absorbed or excreted through the kidneys. The Company operates through the Swedish subsidiaries Wilson Therapeutics Incentive AB and TTM Europe Development AB, as well as through Wilson Therapeutics Inc, a subsidiary based in the United States.